Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Обмен на изследователи2020–2025

PRISAR2 · proactive monitoring of cancer as an alternative to surgery

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2020-04-01 → 2025-03-31
Финансиране от ЕС
2 484 000 €
Участници
25
Схема
MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Нови технологии за мониторинг и стратегии за наблюдение на рака се изследват като алтернатива на хирургичната интервенция. Това помага за по-добрия подбор на пациентите и подобрява качеството им на живот чрез избягване на операциите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

From 2016 -2019, the “first” PRISAR consortium implemented the first Dutch RISE project of H2020 to investigate the use of imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. This PRISAR project provided a career-enabling human resource plethora of inter-disciplinary and inter-sectoral secondments, which resulted in the development, of not only a hybrid probe for image-guided surgery, but also a variety of tools and instruments. We now propose a new project, PRISAR2, to implement the next logical phase of this work, which is to clinically translate new and innovative monitoring technologies from industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new ‘watch and wait’ strategies to study the behaviour of the cancer so that any risks can be minimized. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximize the benefits of an active monitoring policy for both the patient and the healthcare system. When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Here, however, we aim to (a) develop new monitoring technologies from industry so that the surveillance window can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch and wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a better clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this new concept as standard of care and to maximise the benefits of an active monitoring policy.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз